Navigation Links
Neose Announces Presentation of Positive Preclinical Data on,GlycoPEGylated Factor VIIa at the XXI Congress of the International,Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that two poster presentations were presented with its collaborative partner, Novo Nordisk A/S, relating to GlycoPEGylated recombinant Factor VIIa at the XXIst Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland. The data presented demonstrates that GlycoPEGylation(TM) significantly prolongs the active half-life of rFVIIa. GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo Nordisk A/S under a license from Neose.

The posters, which were co-authored by Novo Nordisk and Neose, are titled:

-- Development of long-acting rFVIIa derivatives by GlycoPEGylation(TM)

-- Effect of GlycoPEGylation(TM) on the pharmacokinetic properties of rVIIa

The full poster presentations are available on the Neose corporate website at: http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-presentations

About Coagulation Factor VII

Factor VII/VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant Factor VII was approximately $1 billion in 2006, with Novo Nordisk being the only participant.

About Neose Technologies, Inc.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of
'"/>




Page: 1 2

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/23/2013)... May 24, 2013 3SBio Inc. (NASDAQ: ... a leading China -based biotechnology ... biopharmaceutical products, announced today that, at an extraordinary ... shareholders voted in favor of the proposal to ... plan of merger dated February 8, 2013, among ...
(Date:5/23/2013)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... will present at The Deutsche Bank 38 th Annual ... on May 29, 2013 at 1:30pm Eastern time.  ... public may access Mr. Lindop,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
(Date:5/23/2013)... , May 23, 2013  TeamHealth Medical Call ... triage and nurse advice lines, announces its newly ... physician, nursing and administrative leaders, provides clinical expertise ... and cost-effective services for hospital clients, physician clients ... healthcare system evolves, it,s imperative to continuously advance ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3TeamHealth Medical Call Center Forms Clinical Advisory Committee 2
... FALLS, N.J., Dec. 8, 2011   CANTEL MEDICAL CORP. (NYSE: ... to $6,220,000, or $0.35 per diluted share, on a 30% increase ... October 31, 2011. This compares with net income of $4,975,000, or ... quarter ended October 31, 2010. Andrew Krakauer, Cantel,s ...
... 8, 2011  Amgen (Nasdaq: AMGN ) today announced ... which expired at 12:00 midnight, New York City time, on ... preliminary count by American Stock Transfer & Trust Company, LLC, ... shares of Amgen,s common stock were properly tendered and not ...
Cached Medicine Technology:Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase 2Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase 3Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase 4Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase 5Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase 6Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase 7Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase 8Amgen Announces Preliminary Results of Its Tender Offer 2Amgen Announces Preliminary Results of Its Tender Offer 3Amgen Announces Preliminary Results of Its Tender Offer 4
(Date:5/24/2013)... (PRWEB) May 24, 2013 KC and Monica ... Title Sponsors for FreeRide836. Their oldest sons, Kyle and Austin ... Tracey Russell family and several professional kiteboarders. , KC Craichy ... project. "This has miraculously come together such that virtually everyone ... to participate." , 20 kite boarders will meet at Matheson ...
(Date:5/24/2013)... The Mirena IUD lawyers at the ... FDA has received more than 59,229 complaints since 2004 from ... birth control device known as the Mirena IUD.* , Among ... the women “included ‘expulsion,’ where the IUD came out on ... to an ABC News article. “Abdominal pain is also common, ...
(Date:5/24/2013)... E-Dentists.com has announced the launch of ... Media Surge, a leading medical Internet marketing agency. ... service will focus on providing dentists the help they ... their competitive keywords. The dental SEO analysis covers a ... on what their competitors are doing right. The goal ...
(Date:5/24/2013)... OR (PRWEB) May 24, 2013 ... Sustainable Cards, major competitors in sustainable card material, ... of using forest materials as a sustainable gift ... is to identify industry challenges and increase education ... card programs to support the reduction of carbon ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Started in 1982, ... held in Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is ... starting with supermodel Millie Lewis and her daughter, Carey Lewis ... agents, managers, casting directors, and music professionals including the New ... and XP Media. They are kings of Hollywood and Christian ...
Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2
... for about half of all visits to psychotherapists, and ... with couples.// The therapist helps the couple work on ... perpetuate conflict, explains the March 2007 issue of the ... make little use of psychiatric diagnosis, but they do ...
... of breastfeeding outweigh the risks of virus transmission from HIV-positive ... African nations.// ,A study in Zambia showed ... breast milk ¯ beyond a set time period of ... The study was a collaboration between US universities and University ...
... shows that a form of vitamin A used to treat ... small molecules called microRNAs (miRNAs) in the// leukemic cells. ... miRNAs inhibit the action of two genes important for cancer ... ,The drug is called all-trans-retinoic acid (ATRA) and it ...
... of bioactive compounds in the blood and boost antioxidant ... start// to rival the juice for boosting health. ... rise, particularly in the UK where sales have rocketed ... the antioxidant-rich fruit that has commonly been linked to ...
... in Porirua is not linked to a cluster of cases ... have been treated for typhoid in Porirua and those cases ... of health, regional public health, Wellington, said last night. ... which was being treated very seriously. ,Two of ...
... According to a study published on bmj.com, the second born ... This study also states that there is no big// difference ... second twin born at or after the complete term of ... shortly after birth. ,Many studies have talked about ...
Cached Medicine News:Health News:Breastfeeding Benefits may Outweigh HIV Risk 2Health News:Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down 2Health News:Science Builds Behind Pomegranate Extracts for Health 2
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
4 mm blade. Flat handle....
9 mm button end blade. 15 mm long backcutting blade. Angled at 45 degrees. Flat handle. Designated most popular model or size....
10 mm blade, angled left. Flat handle....
Medicine Products: